Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
dimethyl fumarate (UNII: FO2303MNI2) (monomethyl fumarate - UNII:45IUB1PX8R)
TEVA PHARMACEUTICALS USA, INC.
ORAL
PRESCRIPTION DRUG
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of dimethyl fumarate delayed-release capsules. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1)]. Risk Summary There are no adequate data on the developmental risk associated with the use of dimethyl fumarate delayed-release capsules in pregnant women. In animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when dimethyl fumarate (DMF) was administered during pregnancy and lactation at clinically relevant doses [see Data] . In the U.S. general population, the estimated background risk of major birth defects and miscarr
Dimethyl fumarate delayed-release capsules are available as hard gelatin delayed-release capsules in two strengths containing either 120 mg or 240 mg of dimethyl fumarate. The green and white 120 mg capsules are printed with “BG-12 120 mg” in black ink. The green 240 mg capsules are printed with “BG-12 240 mg” in black ink. Dimethyl fumarate delayed-release capsules are available as follows: 120 mg capsules: 240 mg capsules: Store at 15°C to 30°C (59 to 86°F). Protect the capsules from light. Store in original container.
New Drug Application Authorized Generic
DIMETHYL FUMARATE- DIMETHYL FUMARATE CAPSULE TEVA PHARMACEUTICALS USA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES. DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2013 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults (1) DOSAGE AND ADMINISTRATION Starting dose: 120 mg twice a day, orally, for 7 days (2.1) Maintenance dose after 7 days: 240 mg twice a day, orally (2.1) Swallow dimethyl fumarate delayed-release capsules whole and intact. Do not crush, chew, or sprinkle capsule contents on food (2.1) Take dimethyl fumarate delayed-release capsules with or without food (2.1) DOSAGE FORMS AND STRENGTHS _Delayed-release capsules_: 120 mg and 240 mg (3) CONTRAINDICATIONS Known hypersensitivity to dimethyl fumarate or any of the excipients of dimethyl fumarate delayed-release capsules. (4) WARNINGS AND PRECAUTIONS Anaphylaxis and angioedema: Discontinue and do not restart dimethyl fumarate delayed-release capsules if these occur. (5.1) Progressive multifocal leukoencephalopathy (PML): Withhold dimethyl fumarate delayed-release capsules at the first sign or symptom suggestive of PML. (5.2) Herpes zoster and other serious opportunistic infections: Consider withholding dimethyl fumarate delayed-release capsules in cases of serious infection until the infection has resolved. (5.3) Lymphopenia: Obtain a CBC including lymphocyte count before initiating dimethyl fumarate delayed- release capsules, after 6 months, and every 6 to 12 months thereafter. Consider interruption of dimethyl fumarate delayed-release capsules if lymphocyte counts <0.5 x 10 /L persist for mo Lire le document complet